Potassium channel blocker dofetilide does not abolish ischaemic preconditioning

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 1, 1997, Pages 13-20

  Munch Ellingsen, J ^a   Bugge, E ^a   Lokebo J E ^a   Ytrehus, K ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Heart; Infarct size; Monophasic action potentials; Rabbit

Indexed keywords

DOFETILIDE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0030889861     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709057814     Document Type: Article

References (27)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
2. Thornton JD, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol 1993; 25: 311-20.
3. Van Winkle DM, Chien GL, Wolff RA, Soifer BE, Kuzume K, Davis RF. Cardioprotection provided by adenosine receptor activation is abolished by blockade of the KATP channel. Am J Physiol 1994; 266: H829-H839.
4. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994; 266: H1145-H52.
5. Liu Y, Ytrehus K, Downey JM. Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. J Mol Cell Cardiol 1994; 26: 661-8.
6. Auchampach JA, Grover GJ, Gross GJ. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 1992; 26: 1054-62.
7. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res 1993; 27: 617-22.
8. Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20 Suppl 2: S96-105.
9. Tande PM, Bjornstad H, Yang T, Refsum H. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16: 401-10.
10. Tohse N, Kameyama M, Sekiguchi K, Shearman MS, Kanno M. Protein kinase C activation enhances the delayed rectifier potassium current in guinea-pig heart cells. J Mol Cell Cardiol 1990; 22: 725-34.
11. Habuchi Y, Tanaka H, Furukawa T, Tsujimura Y, Takahashi H, Yoshimura M. Endothelin enhances delayed potassium current via phospholipase C in guinea pig ventricular myocytes. Am J Physiol 1992; 262: H345-H354.
12. Yang T, Tande PM, Lathrop DA, Refsum H. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia-induced electromechanical changes. Cardiovasc Res 1992; 26: 1109-15.
13. Grover GJ, D'Alonzo AJ, Parham CS, Darhenzio RB. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J Cardiovasc Pharmacol 1995; 26: 145-52.
14. Kanaan N, Jenkins J, Kadish A. PACE Pacing. Clin Electrophysiol 1990; 13: 196-206.
15. Mortensen E, Yang T, Refsum H. Class III antiarrhythmic action and inotropy: effects of dofetilide in acute ischemic heart failure in dogs. J Cardiovasc Pharmacol 1992; 19: 216-21.
16. Gwilt M, Blackburn KJ, Burges RA, Higgins AJ, Milne AA, Solca AM. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs. Eur J Pharmacol 1992; 215: 137-44.
17. Tweedie D, Henderson C, Kane K. Glibenclamide, but not class III drugs, prevent ischaemic shortening of the refractory period in guinea-pig hearts. Eur J Pharmacol 1993; 240: 251-7.
18. Reed LJ, Alabaster CT, Barclay PL. Comparative effects of dofetilide and d-sotalol in guineapig Langendorff hearts during simulated ischaemia [abstract]. J Mol Cell Cardiol 1994; 26: CCLIV.
19. Bril A, Faivre JF, Landais L, Gout B. Defibrillatory action of dofetilide and glibenclamide on reperfusion arrhytmias in the rat: blockade of the ATP-sensitive potassium channel as common mechanism [abstract]. J Mol Cell Cardiol 1992; 24 Suppl V: 68.
20. Gibbs CL, Johnson EA. Effect of changes in frequency of stimulation upon rabbit ventricular action potential. Circ Res 1961; 9: 165-70.
21. Edwards G, Weston AH. KATP - fact or arte-fact? New thoughts on the mode of action of the potassium channel openers. Cardiovasc Res 1994; 28: 735-7.
22. Ashcroft FM, Coles B, Kenna S, Proks P, Roper J, Reid J, et al. The KATP and Kv channels are distinct entities: a reply to Edwards and Weston [comment]. Cardiovasc Res 1994; 28: 738-740.
23. Carmeliet E. KATP channels fact or artefact? Cardiovase Res 1994; 28: 925-8.
24. Thornton JD, Thornton CS, Sterling DL, Downey JM. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ Res 1993; 72: 44-9.
25. Walsh RS, Tsuchida A, Daly JJ, Thornton JD, Cohen MV, Downey JM. Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium. Cardiovasc Res 1994; 28: 1337-41.
26. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-33.
27. Rohmann S, Weygandt H, Schelling P, Soei LK, Verdouw PD, Lues I. Involvement of ATP-sensitive potassium channels in preconditioning protection. Basic Res Cardiol 1994; 89: 563-76.